Follow us on Twitter
twitter icon@FreshPatents


Immunotherapy patents

      

This page is updated frequently with new Immunotherapy-related patent applications.




 Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and  prognosticating survival rate in glioblastoma mulztiforme patient after treatment patent thumbnailMethod of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and prognosticating survival rate in glioblastoma mulztiforme patient after treatment
A method of evaluating if a glioblastoma multiforme (gbm) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the gbm patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the gbm patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the gbm patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the gbm patient is determined to have a good prognosis after the treatment when the expression level of the sample from the gbm is lower than the threshold..
China Medical University Hospital


 Immunotherapy with binding agents patent thumbnailImmunotherapy with binding agents
The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals


 Interleukin 15 as selectable marker for gene transfer in lymphocytes patent thumbnailInterleukin 15 as selectable marker for gene transfer in lymphocytes
The present invention relates to the use of interleukin-15 (il-15) as selectable marker for gene transfer, preferably of at least one gene of therapeutic interest, into a mammalian cell or cell line, in particular a human cell or cell line. The present invention furthermore relates to transgenic mammalian cells or cell lines expressing il-15 as selectable marker and co-expressing at least one protein of interest encoded by at least one gene of interest, which is preferably a protein of therapeutic interest.
Chemotherapeutisches Forschungsinstitut Georg-speyer-haus


 Multi-indication mrna cancer immunotherapy patent thumbnailMulti-indication mrna cancer immunotherapy
Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.


 Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines patent thumbnailCombination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
And a compound useful in active or passive tau immunotherapy, a compound useful in active or passive aβ peptide immunotherapy, an nmda receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a tau aggregation inhibitor or an ssri for the treatment of neurodegenerative or cognitive disorders.. .

 Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases patent thumbnailCd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases
The present invention relates to a method for identifying cd8+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd8+ treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd8+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd8+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd8+ treg cell populations of target tissue a, to identify emigrant cd8+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd8+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd8+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd8+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab


 Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases patent thumbnailMethod for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases
The present invention relates to a method for identifying cd4+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd4+ treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd4+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd4+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd4+ treg cell populations of target tissue a, to identify emigrant cd4+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd4+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd4+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd4+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab


 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
Compugen Ltd.


 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Yeast-based immunotherapy and type i interferon sensitivity

Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type i interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeutic compositions and methods for enhancing or improving an individual's response to yeast-based immunotherapy, based on the individual's sensitivity to type 1 interferons (t1ifns).. .
The Regents Of The University Of Colorado, A Body Corporate

Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment

The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding gcn2 and a gene encoding prdm1 is inactivated or repressed.
Cellectis

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes

Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy.
Zander Therapeutics, Inc.

Abscopal effect of uspio theranosis and immunotherapy for cancer treatment

The invention disclosed herein concerns abscopal effect of uspio theranosis and immunotherapy using the same for cancer treatment.. .

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compounds and compositions for treating her2 positive tumors

Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of her2 positive tumors/cancers.
Shanghai Birdie Biotech, Inc.

Generation of hpv-specific t-cells

Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of hpv16 and/or hpv18, including methods with stimulation steps that employ il-7 and il-15, but not il-6 and/or il-12.
Baylor College Of Medicine

Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor

Contemplated cancer treatments comprise recursive analysis of patient-, cancer-, and location-specific neoepitopes from various biopsy sites of a patient after treatment or between successive rounds of immunotherapy and/or chemotherapy to inform further immunotherapy. Recursive analysis preferably includes various neoepitope attributes to so identify treatment relevant neoepitopes..
Nantomics, Llc

Immunotherapy of cancer using genetically engineered gd2-specific t cells

The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside gd2 antigen. In specific embodiment, t cells having a chimeric receptor that targets gd2 is employed.
Baylor College Of Medicine

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
Celgene Corporation

Gitr antigen binding proteins

Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma.
Immatics Biotechnologies Gmbh

Peanut formulations and uses thereof

The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy..
Aimmune Therapeutics, Inc.

Method for generating t-cells compatible for allogenic transplantation

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
Cellectis

Claudin-6-specific immunoreceptors and t cell epitopes

The present invention provides claudin-6-specific immunoreceptors (t cell receptors and artificial t cell receptors (chimeric antigen receptors; cars)) and t cell epitopes which are useful for immunotherapy.. .
Ganymed Pharmceuticals Ag

Tc-ptp inhibitors as apc activators for immunotherapy

The invention encompasses the novel class of compounds represented by the formula (i) below, which are inhibitors of the tc-ptp enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing tc-ptp mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases..
The Royal Institute For The Advancement Of Learning / Mcgill University

Antibody-drug conjugates and uses thereof

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to trop-2 or ceacam5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg.
Immunomedics, Inc.

Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents

Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness.
Best Pet Rx Ip, Inc. (50% Interest)

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.

Predicting response to epigenetic drug therapy

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy.
The Johns Hopkins University

Method for reconstructing immune function using pluripotent stem cells

According to the present invention, there are provided a method for producing a human t cell, which comprises the steps of inducing an ips cell from a human t cell, and differentiating the ips cell into a t cell; a pharmaceutical composition comprising the t cell produced by the method; and a method for cell-based immunotherapy using the method.. .
The University Of Tokyo

Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy

Disclosed herein is a vaccine comprising an antigen and pd1 antibody and/or pdl1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject.
Inovio Pharmaceuticals, Inc.

Novel methods of identifying patients responsive to immunotherapeutic strategies

The invention includes a method of determining whether a mammal's cancerous tumor is associated with a hypermutator phenotype (i.e., harboring a large number of mutations) for the dna polymerase epsilon (pole) gene as compared to normal cells. The invention further includes a method of selecting patients harboring an immunogenic tumor that is responsive to immunotherapy..
Yale University

Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant cd8 t-cells

A previously unknown t cell receptor (tcr) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mtor inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative tcr activation pathway uniquely exists in a subset of cd8 t cells expanded in the setting of chronic rejection or rheumatoid arthritis.

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Method for emulsifying a triepitope peptide with montanide and kits for performing the same

The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and montanide as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.. .
Vaxon Biotech

Kidney-specific tumor vaccine directed against kidney tumor antigen g-250

This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California

Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof

Provided are novel human islet amyloid polypeptide, also known as amylin and iapp and proiapp respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for iapp and/or proiapp are also disclosed.
Neurimmune Holding Ag

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh



Immunotherapy topics:
  • Immunotherapy
  • Therapeutics
  • Antibodies
  • Immune Response
  • Monoclonal
  • Monoclonal Antibody
  • Stimulator
  • Immunostimulator
  • Compatibility
  • Histocompatibility
  • Specificity
  • Major Histocompatibility Complex
  • Radiation Therapy
  • Treatments
  • Amino Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.7338

    file did exist - 2811

    0 - 1 - 57